Gabbard Unveils Classified Intel on 120 Secret U.S. Biolabs Worldwide

Clear Facts

• Director of National Intelligence Tulsi Gabbard announced the discovery of previously classified evidence revealing U.S. government funding of more than 120 biological laboratories across over 30 countries.
• The intelligence includes facilities in Ukraine that were previously flagged by officials as potentially vulnerable during the ongoing conflict with Russia.
• This represents the first public disclosure of the full scope and scale of America’s global biolab network.

Director of National Intelligence Tulsi Gabbard made a startling announcement Friday, revealing that her office has uncovered previously classified evidence of extensive U.S. government involvement in biological research facilities around the world. The intelligence shows American funding flowing to more than 120 biolabs spanning over 30 countries.

The disclosure marks a significant moment in transparency regarding America’s international biological research programs. For years, questions have swirled around the extent and nature of U.S. involvement in foreign biolabs, particularly following concerns raised during the COVID-19 pandemic about the origins of the virus and international research practices.

Among the facilities identified are several located in Ukraine, a detail that raises serious national security questions given the ongoing war with Russia. Intelligence officials had previously warned that these Ukrainian facilities could become vulnerable targets or sources of concern during military conflict, though the full extent of their operations remained classified until now.

The revelation comes as Gabbard continues her mission to bring greater accountability and transparency to America’s intelligence apparatus. Her willingness to declassify this information represents a departure from the traditional secrecy that has surrounded U.S. biodefense programs and international research partnerships.

The 120-plus laboratories operate across diverse regions and geopolitical contexts, though specific details about individual facilities, their research focus, and security protocols have not yet been fully disclosed. The sheer scale of the network suggests a far more extensive international biological research infrastructure than previously acknowledged to the American public.

Critics of such programs have long expressed concerns about biosafety protocols, dual-use research that could have both civilian and military applications, and the potential for accidents or intentional misuse. Supporters argue that international biological research cooperation is essential for disease surveillance, pandemic preparedness, and scientific advancement.

The timing of this disclosure is particularly significant given ongoing debates about U.S. foreign policy, international research standards, and the need for oversight of taxpayer-funded programs operating beyond American borders. It raises fundamental questions about congressional awareness and approval of these extensive international commitments.

The intelligence community under Gabbard’s leadership appears committed to a new era of disclosure, though many questions remain about what other classified programs may still be hidden from public view. The full implications of this biolab network—including costs, research conducted, and strategic objectives—will likely become subjects of intense congressional scrutiny in the coming months.

Let us know what you think, please share your thoughts in the comments below.